Cargando…
S291: LONG-TERM SAFETY AND EFFICACY OF CMV/EBV-SPECIFIC T CELLS FOR CMV AND EBV CO-REACTIVATION AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION
Autores principales: | Xuying, Pei, Zhao, Xiangyu, LV, Meng, Liu, Jing, Xu, Lanping, Wang, Yu, Zhang, Xiao-Hui, Huang, Xiao-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10428260/ http://dx.doi.org/10.1097/01.HS9.0000968076.74193.6a |
Ejemplares similares
-
Immune recovery and the risk of CMV/ EBV reactivation in children post allogeneic haematopoietic stem cell transplantation
por: Janeczko, Małgorzata, et al.
Publicado: (2016) -
CMV Infection and CMV-Specific Immune Reconstitution Following Haploidentical Stem Cell Transplantation: An Update
por: Luo, Xiao-Hua, et al.
Publicado: (2021) -
The prevalence of EBV and CMV DNA in epithelial ovarian cancer
por: Ingerslev, Kasper, et al.
Publicado: (2019) -
Third-party CMV- and EBV-specific T-cells for first viral reactivation after allogeneic stem cell transplant
por: Jiang, Wei, et al.
Publicado: (2022) -
Adoptive transfer of rapidly-generated multivirus-specific T cells to treat Adv, EBV, CMV, BK and HHV6 infections of HSCT recipients
por: Papadopoulou, Anastasia, et al.
Publicado: (2013)